Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HK-1 Series
- Development stage
- Preclinical
- Lead developer
- Curome Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HK-1 Series is a preclinical-stage therapeutic program developed by Curome Biosciences, targeting NADH:quinone oxidoreductase 1 (NQO1) for the treatment of Primary Mitochondrial Diseases (PMD). The mechanism involves the modulation of NQO1, a flavoenzyme critical for maintaining cellular redox homeostasis by catalyzing the two-electron reduction of quinones to hydroquinones. By utilizing NQO1, the therapy aims to improve mitochondrial function and energy metabolism, which are typically compromised in patients with PMD. The program is currently undergoing GLP (Good Laboratory Practice) toxicity studies to support further clinical development.
- Other names
- HK-1HK1HK 1
02
Targets
NQO1
Beyond the preview
Go deeper on HK-1 Series.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HK-1 Series.